期刊
FUNCTION
卷 4, 期 3, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/function/zqad015
关键词
personalized treatment; individualized therapy; targeted therapy; pancreas; inflammation; translational medicine; biomarker; pancreatic cancer
Acute pancreatitis is a significant burden with no specific therapy. A paradigm shift towards personalized treatment approaches and clinical trials should be considered. The development of precision medicine in acute pancreatitis requires the establishment of an expert committee to coordinate activities and optimize patient care.
Acute pancreatitis (AP) continues to present a substantial burden to patients and healthcare personnel. Despite its occasionally severe progression and high mortality rate, there is no specific therapy that could be routinely applied in patients with AP. Here, we review treatment possibilities in AP, describe how the treatment approaches have changed in pancreatic cancer as an analogy, and point out potential causes for the failure of clinical trials on AP. We highlight that instead of attempting to discover generalized treatment options that could be used in any AP patient, it is time for a paradigm shift in the treatment of AP, which would help to focus more on individual patients or specific patient subpopulations when designing clinical trials and therapeutic approaches (similarly as in pancreatic cancer). Since the recruitment of specific patient subpopulations with AP could take excessive time if clinical centers work separately, the development of precision medicine in AP would require to establish an expert committee, eg, Pancreatitis Precision Medicine Interest Group, which could organize and coordinate the activities of the joined centers. With the joined forces of expert clinicians and leading centers, a new era could start in the treatment of AP, in which personalized treatment options could be discovered and introduced to efficiently reduce the burden of the disease on patients and healthcare workers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据